68Ga-FAPI PET/CT:两种DOTA类FAP靶向药物在多种癌症患者中的生物分布与初步剂量学估算
本研究基于2例患者估算68Ga-FAPI-2与68Ga-FAPI-4的初步剂量学,并对分别接受68Ga-FAPI-2(n=25)或68Ga-FAPI-4(n=25)的肿瘤患者行注射后1小时PET/CT,其中6例有同体18F-FDG扫描。结果显示200 MBq的68Ga-FAPI-2或68Ga-FAPI-4对应约3-4 mSv等效剂量,肿瘤摄取与18F-FDG几乎相等(平均SUVmax 7.41 vs 7.37,无统计学显著差异),而脑、肝、口咽黏膜本底显著更低。
要点
- 200 MBq的68Ga-FAPI-2或68Ga-FAPI-4对应约3-4 mSv等效剂量
- 68Ga-FAPI-2从注射后1到3小时肿瘤摄取下降75%,68Ga-FAPI-4肿瘤滞留更久(洗脱25%)
- 注射后1小时两种示踪剂肿瘤/本底比值表现相当,肿瘤摄取与18F-FDG几乎相等
核心结论
- FAPI PET/CT是肿瘤患者成像的一种新诊断方法,与18F-FDG不同,检查前无需饮食或禁食准备,且图像采集可能在示踪剂注射后数分钟即可开始。
- 肿瘤/本底对比度等于或甚至优于18F-FDG。
研究设计与样本
- 基于2例患者,使用QDOSE剂量学软件套件在示踪剂注射后0.2、1和3小时进行68Ga-FAPI-2与68Ga-FAPI-4的初步剂量学估算。
- 对肿瘤患者分别在注射68Ga-FAPI-2(n=25)或68Ga-FAPI-4(n=25)后1小时行PET/CT扫描,其中6例患者有同体相关的18F-FDG扫描(同样在注射后1小时采集)。
- 正常组织在16个器官的实质内放置2 cm球状感兴趣区;肿瘤病灶采用阈值分割感兴趣区量化SUVmean和SUVmax。
主要发现
- 与18F-FDG、68Ga-DOTATATE和68Ga-PSMA-11的文献值相似,200 MBq的68Ga-FAPI-2或68Ga-FAPI-4检查对应约3-4 mSv等效剂量。
- 经肾脏快速清除后,正常器官示踪剂摄取低,注射后10分钟至3小时之间仅有极小变化。
- 68Ga-FAPI-2从注射后1到3小时肿瘤摄取下降75%,而68Ga-FAPI-4肿瘤滞留延长(洗脱25%)。
- 注射后1小时两种68Ga-FAPI示踪剂的肿瘤/本底比值表现相当。
- 与18F-FDG相比,肿瘤摄取几乎相等(平均SUVmax:18F-FDG为7.41,68Ga-FAPI-2为7.37;无统计学显著差异);68Ga-FAPI的脑(11.01 vs. 0.32)、肝(2.77 vs. 1.69)和口咽黏膜(4.88 vs. 2.57)本底摄取显著更低,其他器官在18F-FDG与68Ga-FAPI之间无相关差异。
临床怎么用
- 作者指出FAPI PET/CT是肿瘤患者成像的一种新诊断方法,与18F-FDG不同,检查前无需饮食或禁食准备,且图像采集可能在示踪剂注射后数分钟即可开始。
- 作者指出肿瘤/本底对比度等于或甚至优于18F-FDG。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts of several tumor entities. The recent development of quinoline-based PET tracers that act as FAP inhibitors (FAPIs) demonstrated promising results preclinically and already in a few clinical cases. Consequently, these tracers are now applied in our hospital to amend the diagnostics of cancer patients facing the limitations of standard examinations. Here, we analyze the tissue biodistribution and preliminary dosimetry of 2 members of this new class of PET radiopharmaceutical. Methods: A preliminary dosimetry estimate for 68Ga-FAPI-2 and 68Ga-FAPI-4 was based on 2 patients examined at 0.2, 1, and 3 h after tracer injection using the QDOSE dosimetry software suit. Further PET/CT scans of tumor patients were acquired 1 h after injection of either 68Ga-FAPI-2 (n = 25) or 68Ga-FAPI-4 (n = 25); for 6 patients an intraindividual related 18F-FDG scan (also acquired 1 h after injection) was available. For the normal tissue of 16 organs, a 2-cm spheric volume of interest was placed in the parenchyma; for tumor lesions, a threshold-segmented volume of interest was used to quantify SUVmean and SUVmaxResults: Similar to literature values for 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA-11, an examination with 200 MBq of 68Ga-FAPI-2 or 68Ga-FAPI-4 corresponds to an equivalent dose of approximately 3-4 mSv. After a fast clearance via the kidneys, the normal organs showed a low tracer uptake with only minimal changes between 10 min and 3 h after injection. In 68Ga-FAPI-2, the tumor uptake from 1 to 3 h after injection decreased by 75%, whereas the tumor retention was prolonged with 68Ga-FAPI-4 (25% washout). Regarding tumor-to-background ratios, at 1 h after injection both 68Ga-FAPI tracers performed equally. In comparison to 18F-FDG, the tumor uptake was almost equal (average SUVmax, 7.41 for 18F-FDG and 7.37 for 68Ga-FAPI-2; not statistically significant); the background uptake in brain (11.01 vs. 0.32), liver (2.77 vs. 1.69), and oral/pharyngeal mucosa (4.88 vs. 2.57) was significantly lower with 68Ga-FAPI. Other organs did not relevantly differ between 18F-FDG and 68Ga-FAPI. Conclusion: FAPI PET/CT is a new diagnostic method in imaging cancer patients. In contrast to 18F-FDG, no diet or fasting in preparation for the examination is necessary, and image acquisition can potentially be started a few minutes after tracer application. Tumor-to-background contrast ratios were equal to or even better than those of 18F-FDG.
引用
- Giesel FL, Kratochwil C, Lindner T, et al. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2018. PMID: 30072500. doi:10.2967/jnumed.118.215913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。